Navigation Links
Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
Date:8/6/2013

CRANBURY, N.J., Aug. 6, 2013 /PRNewswire/ -- Oncobiologics, Inc. and inVentiv Health today announced a broad strategic partnership around clinical development for all assets in Oncobiologic's pipeline.  The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules.  Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials.  As the assets are commercialized, the partnership will be broadened to include inVentiv's significant commercialization capabilities in select countries.  This will position Oncobiologics attractively in seeking future commercial partners.

The current biosimilar assets include generic versions of Humira®, Rituxan®, Avastin®, Herceptin® and Erbitux®. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion.

"After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets.  inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch. With their willingness to share in the risk/reward of our development programs, our firms are a perfect fit, both technically and culturally," said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.

Ray Hill, President, inVentiv Health Clinical added, "We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium.  With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv's broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts."

About Oncobiologics, Inc.
Oncobiologics is a privately-held biopharmaceutical company that has developed a pipeline of biosimilars and is developing next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq. ft. R&D facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team.  With 7,000 passionate employees operating in more than 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.  http://www.inventivhealthclinical.comContact:Rick GregoryDirector of Marketing & CommunicationsOncobiologics, Inc.rickgregory@oncobiologics.com


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Huahai and Oncobiologics Create Broad Biosimilars Partnership
2. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
3. inVentiv Health Partners With Medikly To Speed Clinical Trials By Accelerating The Recruitment Of Investigators
4. inVentiv Health Forms Strategic Alliance With Bell Medical Solutions, One Of Japans Top Clinical Research Organizations
5. PharmaNet/i3 Renamed inVentiv Health Clinical
6. inVentiv Health Strengthens Clinical Leadership Team
7. inVentiv Medical Management Forms Partnership with Vital Decisions
8. Frost & Sullivan Analyzes Emerging Opportunities for Stakeholders in the Transforming Healthcare Industry
9. Human Circuit Recognized as Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2013
10. The Center for Ultrasound Research and Education (CURE) Receives Institutional Accreditation from the Accrediting Bureau of Health Education Schools
11. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... CINCINNATI (PRWEB) , ... May 28, 2020 , ... When ... something was missing… franchisees were able to help provide the physical care services needed ... company to care for the houses themselves. Now Fitzgerald is pleased to be in ...
(Date:5/28/2020)... ... May 28, 2020 , ... Reinforcing its commitment ... latest white paper, Caring for our Children: A Look at Patient Experience in ... pediatric settings and highlights key findings to help organizations achieve their experience goals. ...
(Date:5/27/2020)... ... ... Focus Technology , a leading provider of next-generation IT infrastructure, managed ... the American Heart Association’s 2020 Boston Heart Walk, earning them the distinction ... is sponsoring the AHA event. The sponsorship donation will be used to help those ...
Breaking Medicine Technology:
(Date:5/25/2020)... ... May 23, 2020 , ... Winemaker Grant Long Jr. ... wanted to present something whimsical and delicious in these complicated times,” he said, in ... ($34.99) and 2018 Grenache ($24.99). The Chardonnay and Red Wine Blend are sourced in ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... first milestone to deliver over one million FDA-compliant face shields — designed, engineered ... Shields meet the critical need for personal protective equipment (PPE) for both front-line ...
(Date:5/21/2020)... ... May 21, 2020 , ... A Safe Haven Foundation (ASHF) has ... $5 million AbbVie COVID-19 Community Resilience Fund. The fund was created in March to ... frontline homeless workers in service to vulnerable populations in hard-hit communities. , “We ...
(Date:5/21/2020)... ... 2020 , ... ESO , the leading data and software company serving ... 2020 ESO Fire Service Index . The Index looks at key trends across ... turnout time and travel time, the most common property types visited and estimated property ...
(Date:5/21/2020)... ... 2020 , ... A new report from Kalorama Information, a market ... in the point of care test industry. Given the need to diagnose patients ... point-of-care more important than in the past, according to the market researcher. ...
Breaking Medicine News(10 mins):